Previous Close | 3.4900 |
Open | 3.5200 |
Bid | 3.2700 x 1800 |
Ask | 3.4100 x 1800 |
Day's Range | 3.2800 - 3.5700 |
52 Week Range | 2.8700 - 8.3800 |
Volume | |
Avg. Volume | 370,937 |
Market Cap | 127.97M |
Beta (5Y Monthly) | 2.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7310 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.00 |
Conference Call Scheduled for Today at 4:30 p.m. Eastern TimeBERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent business events. Recent Corporate Highlights: CorMedix announced on March 28 t
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its international operations: Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10th. Liz Hurlburt, EVP of Clinical Operati
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2022, after the market close on Thursday, May 12, 2022, and will host a corporate update conference call at 4:30pm Eastern Time. Thursday, May 12th @ 4: